The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors

Journal of Bone and Mineral Research

Volumn 31, Issue 4, 2016, Pages 815-827

  Toscani, Denise ^a   Palumbo, Carla ^b   Dalla Palma, Benedetta ^a,c   Ferretti, Marzia ^b   Bolzoni, Marina ^a   Marchica, Valentina ^a   Sena, Paola ^b   Martella, Eugenia ^c   Mancini, Cristina ^c   Ferri, Valentina ^a,d   Costa, Federica ^a   Accardi, Fabrizio ^a,c   Craviotto, Luisa ^a   Aversa, Franco ^a,c   Giuliani, Nicola ^a,c  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Autophagy; Cancer Induced Bone Disease; Multiple Myeloma; Osteocytes; Proteasome Inhibitors

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CASPASE 3; DEXAMETHASONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOMODULATING AGENT; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3BETA; PARATHYROID HORMONE[1-34]; THALIDOMIDE; UNCLASSIFIED DRUG; PROTEASOME INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOPHAGY; BONE BIOPSY; BONE DISEASE; CELL VIABILITY; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VIVO STUDY; MULTIPLE MYELOMA; OSTEOCYTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; CELL SURVIVAL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; AUTOPHAGY; BORTEZOMIB; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; OSTEOCYTES; PROTEASOME INHIBITORS;

EID: 84950122575     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2741     Document Type: Article

References (57)

1. Roodman GD,. Pathogenesis of myeloma bone disease. Leukemia. 2009; 23 (3): 435-41.
2. Giuliani N, Rizzoli V, Roodman GD,. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006; 108 (13): 3992-6.
3. Bonewald LF,. The amazing osteocyte. J Bone Miner Res. 2011; 26 (2): 229-38.
4. Heino TJ, Hentunen TA,. Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther. 2008; 3 (2): 131-45.
5. Noble BS, Reeve J,. Osteocyte function, osteocyte death and bone fracture resistance. Mol Cell Endocrinol. 2000; 159 (1-2): 7-13.
6. Palumbo C, Palazzini S, Marotti G,. Morphological study of intercellular junctions during osteocyte differentiation. Bone. 1990; 11 (6): 401-6.
7. Teti A, Zallone A,. Do osteocytes contribute to bone mineral homeostasis ? Osteocytic osteolysis revisited. Bone. 2009; 44 (1): 11-6.
8. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW,. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005; 16 (3): 319-27.
9. Chen H, Senda T, Kubo KY,. The osteocyte plays multiple roles in bone remodeling and mineral homeostasis. Med Mol Morphol. 2015; 48 (2): 61-8.
10. Weinstein RS, Nicholas RW, Manolagas SC,. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000; 85 (8): 2907-12.
11. Tomkinson A, Reeve J, Shaw RW, Noble BS,. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997; 82 (9): 3128-35.
12. Emerton KB, Hu B, Woo AA, et al., Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone. 2010; 46 (3): 577-83.
13. O'Brien CA, Jia D, Plotkin LI, et al., Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004; 145 (4): 1835-41.
14. Canalis E, Delany AM,. Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci. 2002; 966: 73-81.
15. Lane NE, Yao W, Balooch M, et al., Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res. 2006; 21 (3): 466-76.
16. Tatsumi S, Ishii K, Amizuka N, et al., Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007; 5 (6): 464-75.
17. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC,. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology. 2010; 151 (6): 2641-9.
18. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37 (2): 148-58.
19. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC,. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104 (4): 439-46.
20. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T,. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999; 104 (10): 1363-74.
21. Plotkin LI, Manolagas SC, Bellido T,. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006; 39 (3): 443-52.
22. Pengo N, Scolari M, Oliva L, et al., Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol. 2013; 14 (3): 298-305.
23. Srinivas V, Bohensky J, Zahm AM, Shapiro IM,. Autophagy in mineralizing tissues: microenvironmental perspectives. Cell Cycle. 2009; 8 (3): 391-3.
24. Tsujimoto Y, Shimizu S,. Another way to die: autophagic programmed cell death. Cell Death Differ. 2005; 12 (Suppl 2): 1528-34.
25. Onal M, Piemontese M, Xiong J, et al., Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem. 2013; 288 (24): 17432-40.
26. Xia X, Kar R, Gluhak-Heinrich J, et al., Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res. 2010; 25 (11): 2479-88.
27. Yao W, Dai W, Jiang JX, Lane NE,. Glucocorticoids and osteocyte autophagy. Bone. 2013; 54 (2): 279-84.
28. Giuliani N, Ferretti M, Bolzoni M, et al., Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012; 26 (6): 1391-401.
29. Garrett IR, Chen D, Gutierrez G, et al., Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003; 111 (11): 1771-82.
30. Giuliani N, Morandi F, Tagliaferri S, et al., The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007; 110 (1): 334-8.
31. Zangari M, Esseltine D, Lee CK, et al., Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005; 131 (1): 71-3.
32. Shimazaki C, Uchida R, Nakano S, et al., High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia. 2005; 19 (6): 1102-3.
33. Heider U, Kaiser M, Muller C, et al., Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006; 77 (3): 233-8.
34. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G,. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006; 7 (2): 109-14.
35. Bodine PV, Vernon SK, Komm BS,. Establishment and hormonal regulation of a conditionally transformed preosteocytic cell line from adult human bone. Endocrinology. 1996; 137 (11): 4592-604.
36. Bonewald LF,. Establishment and characterization of an osteocyte-like cell line, MLO-Y4. J Bone Miner Metab. 1999; 17 (1): 61-5.
37. Rosser J, Bonewald LF,. Studying osteocyte function using the cell lines MLO-Y4 and MLO-A5. Methods Mol Biol. 2012; 816: 67-81.
38. Sena P, Manfredini G, Benincasa M, et al., Up-regulation of the chemo-attractive receptor ChemR23 and occurrence of apoptosis in human chondrocytes isolated from fractured calcaneal osteochondral fragments. J Anat. 2014; 224 (6): 659-68.
39. Yang W, Harris MA, Heinrich JG, Guo D, Bonewald LF, Harris SE,. Gene expression signatures of a fibroblastoid preosteoblast and cuboidal osteoblast cell model compared to the MLO-Y4 osteocyte cell model. Bone. 2009; 44 (1): 32-45.
40. Terpos E, Christoulas D, Kastritis E, et al., The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. Am J Hematol. 2014; 89 (1): 34-40.
41. Munemasa S, Sakai A, Kuroda Y, et al., Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008; 33 (1): 129-36.
42. Engelhardt M, Terpos E, Kleber M, et al., European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014; 99 (2): 232-42.
43. Zangari M, Yaccoby S, Pappas L, et al., A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011; 96 (2): 333-6.
44. Pennisi A, Ling W, Li X, et al., Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One. 2010; 5 (12): e15233.
45. Zangari M, Berno T, Yang Y, et al., Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone. 2014; 61: 39-43.
46. Jiang P, Mizushima N,. LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells. Methods. 2015; 75: 13-8.
47. Calle JD, Bellido T, Roodman GDD,. Direct cell-to-cell interactions between osteocytes and multiple myeloma (MM) cells upregulate Sost and downregulate OPG expression in osteocytes: evidence for osteocytic contributions to MM-induced bone disease. Blood. 2013; 122 (21): 1.
48. Hocking LJ, Whitehouse C, Helfrich MH,. Autophagy: a new player in skeletal maintenance ? J Bone Miner Res. 2012; 27 (7): 1439-47.
49. Gioia R, Panaroni C, Besio R, et al., Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells. 2012; 30 (7): 1465-76.
50. Selimovic D, Porzig BB, El-Khattouti A, et al., Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 2013; 25 (1): 308-18.
51. Auner HW, Cenci S,. Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. Br J Haematol. 2015; 168 (1): 14-25.
52. Periyasamy-Thandavan S, Jackson WH, Samaddar JS, et al., Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 2010; 6 (1): 19-35.
53. Hui B, Shi YH, Ding ZB, et al., Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer. 2012; 118 (22): 5560-71.
54. Kao C, Chao A, Tsai CL, et al., Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell Death Dis. 2014; 5: e1510.
55. Kabeya Y, Mizushima N, Ueno T, et al., LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000; 19 (21): 5720-8.
56. Tanida I, Ueno T, Kominami E,. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 2004; 36 (12): 2503-18.
57. Delgado-Calle J, Anderson J, Plotkin LI, Bellido T, Roodman GD,. Notch- and TNF alpha-activated signaling pathways mediate osteocyte apoptosis triggered by multiple myeloma cells. Blood. 2014; 124 (21): 3.